ALLG trial: Ibrutinib plus R-mini-CHOP in older patients with newly diagnosed DLBCL
We summarize key results from the phase II ALLG study of ibrutinib + R-mini-CHOP in older patients with newly diagnosed DLBCL.
Related Articles
A meta-analysis of the utility of cryotherapy for preventing peripheral neuropathy among breast cancer patients receiving paclitaxel and nab-paclitaxel
Breast Cancer Research and Treatment – Cryotherapy with taxane infusion is a noninvasive strategy for preventing peripheral neuropathy (PN), but the efficacy of this approach…
Friends Announces Janet Woodcock and Paul Kim’s Appointment to Board of Directors – Friends of Cancer Research
Washington, DC – Friends of Cancer Research (Friends) is excited to announce the addition of Dr. Janet Woodcock, Former Director of the Center for Drug…
Everolimus Plus Lanreotide Extends PFS in Advanced GEP-NETs
Everolimus plus lanreotide demonstrated an improved PFS compared with everolimus monotherapy in gastroenteropancreatic neuroendocrine tumors.
Leading Scientifically Rigorous Research in Novel Brain Cancer Therapies
Shwetal Mehta, PhD, highlights early phase clinical trials, biomarker testing strategies, and potential next steps for research in the brain cancer field.
What causes chronic inflammation and why it matters
You could be experiencing chronic inflammation and not realize it. Learn the signs and how it can affect your health.
Exploring a New Generation of Patient-Centric Cancer Clinical Trials
Register for Exploring a New Generation of Patient-Centric Cancer Clinical Trials, a virtual patient advocacy event hosted by the AACR.
As Mounting Evidence Suggests PFAS May Cause Cancer, Experts Call for More Action
A growing body of research suggests that exposure to PFAS, commonly called “forever chemicals,” may increase a person’s risk of developing cancer.
